AAV-mediated local delivery of interferon-β for the treatment of retinoblastoma in preclinical models

Chie-Schin Shih, Nikia Laurie, Jeremy Holzmacher, Yunyu Spence, Amit C. Nathwani, Andrew M. Davidoff, Michael A. Dyer

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Interferon-β (IFN-β) has been found to have anti-tumor properties against a variety of malignancies through different mechanisms. However, clinical trials involving systemic administration of IFN-β have been hampered by secondary toxicity and the short half-life of IFN-β in the circulation. In order to circumvent these limitations, we have developed an adeno-associated viral (AAV) vector gene-therapy approach to deliver IFN-β to tumors. In this study, we tested the efficacy of AAV-mediated local delivery of IFN-β for the treatment of retinoblastoma in preclinical models. Retinoblastoma is an ideal candidate for gene-therapy-based anti-cancer treatment because target cell transduction and, therefore, IFN-β delivery can be contained within the ocular environment, thereby minimizing systemic toxicity. We report here that retinoblastoma cell lines exhibit pleiotropic responses to IFN-β consistent with previous studies on a variety of tumor cell lines. Intravitreal injection of AAV-IFN-β resulted in efficient retinal infection and sustained IFN-β production in the eye with minimal systemic exposure. Vector spread outside of the eye was not detected. Using our orthotopic xenograft model of retinoblastoma, we found that intravitreal injection of AAV-IFN-β had a potent anti-tumor effect in vivo. These data suggest that AAV-mediated delivery of IFN-β may provide a complementary approach to systemic chemotherapy which is the standard of care for retinoblastoma around the world.

Original languageEnglish (US)
Pages (from-to)43-52
Number of pages10
JournalNeuroMolecular Medicine
Volume11
Issue number1
DOIs
StatePublished - Mar 2009

Fingerprint

Retinoblastoma
Interferons
Therapeutics
Intravitreal Injections
Neoplasms
Genetic Therapy
Viral Genes
Standard of Care
Tumor Cell Line
Heterografts
Half-Life
Clinical Trials
Drug Therapy
Cell Line

Keywords

  • AAV
  • Gene therapy
  • Interferon-β
  • Retinoblastoma

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Molecular Medicine
  • Neurology

Cite this

AAV-mediated local delivery of interferon-β for the treatment of retinoblastoma in preclinical models. / Shih, Chie-Schin; Laurie, Nikia; Holzmacher, Jeremy; Spence, Yunyu; Nathwani, Amit C.; Davidoff, Andrew M.; Dyer, Michael A.

In: NeuroMolecular Medicine, Vol. 11, No. 1, 03.2009, p. 43-52.

Research output: Contribution to journalArticle

Shih, Chie-Schin ; Laurie, Nikia ; Holzmacher, Jeremy ; Spence, Yunyu ; Nathwani, Amit C. ; Davidoff, Andrew M. ; Dyer, Michael A. / AAV-mediated local delivery of interferon-β for the treatment of retinoblastoma in preclinical models. In: NeuroMolecular Medicine. 2009 ; Vol. 11, No. 1. pp. 43-52.
@article{3fb6ce6a493b415aa313d29c69bd9441,
title = "AAV-mediated local delivery of interferon-β for the treatment of retinoblastoma in preclinical models",
abstract = "Interferon-β (IFN-β) has been found to have anti-tumor properties against a variety of malignancies through different mechanisms. However, clinical trials involving systemic administration of IFN-β have been hampered by secondary toxicity and the short half-life of IFN-β in the circulation. In order to circumvent these limitations, we have developed an adeno-associated viral (AAV) vector gene-therapy approach to deliver IFN-β to tumors. In this study, we tested the efficacy of AAV-mediated local delivery of IFN-β for the treatment of retinoblastoma in preclinical models. Retinoblastoma is an ideal candidate for gene-therapy-based anti-cancer treatment because target cell transduction and, therefore, IFN-β delivery can be contained within the ocular environment, thereby minimizing systemic toxicity. We report here that retinoblastoma cell lines exhibit pleiotropic responses to IFN-β consistent with previous studies on a variety of tumor cell lines. Intravitreal injection of AAV-IFN-β resulted in efficient retinal infection and sustained IFN-β production in the eye with minimal systemic exposure. Vector spread outside of the eye was not detected. Using our orthotopic xenograft model of retinoblastoma, we found that intravitreal injection of AAV-IFN-β had a potent anti-tumor effect in vivo. These data suggest that AAV-mediated delivery of IFN-β may provide a complementary approach to systemic chemotherapy which is the standard of care for retinoblastoma around the world.",
keywords = "AAV, Gene therapy, Interferon-β, Retinoblastoma",
author = "Chie-Schin Shih and Nikia Laurie and Jeremy Holzmacher and Yunyu Spence and Nathwani, {Amit C.} and Davidoff, {Andrew M.} and Dyer, {Michael A.}",
year = "2009",
month = "3",
doi = "10.1007/s12017-009-8059-0",
language = "English (US)",
volume = "11",
pages = "43--52",
journal = "NeuroMolecular Medicine",
issn = "1535-1084",
publisher = "Humana Press",
number = "1",

}

TY - JOUR

T1 - AAV-mediated local delivery of interferon-β for the treatment of retinoblastoma in preclinical models

AU - Shih, Chie-Schin

AU - Laurie, Nikia

AU - Holzmacher, Jeremy

AU - Spence, Yunyu

AU - Nathwani, Amit C.

AU - Davidoff, Andrew M.

AU - Dyer, Michael A.

PY - 2009/3

Y1 - 2009/3

N2 - Interferon-β (IFN-β) has been found to have anti-tumor properties against a variety of malignancies through different mechanisms. However, clinical trials involving systemic administration of IFN-β have been hampered by secondary toxicity and the short half-life of IFN-β in the circulation. In order to circumvent these limitations, we have developed an adeno-associated viral (AAV) vector gene-therapy approach to deliver IFN-β to tumors. In this study, we tested the efficacy of AAV-mediated local delivery of IFN-β for the treatment of retinoblastoma in preclinical models. Retinoblastoma is an ideal candidate for gene-therapy-based anti-cancer treatment because target cell transduction and, therefore, IFN-β delivery can be contained within the ocular environment, thereby minimizing systemic toxicity. We report here that retinoblastoma cell lines exhibit pleiotropic responses to IFN-β consistent with previous studies on a variety of tumor cell lines. Intravitreal injection of AAV-IFN-β resulted in efficient retinal infection and sustained IFN-β production in the eye with minimal systemic exposure. Vector spread outside of the eye was not detected. Using our orthotopic xenograft model of retinoblastoma, we found that intravitreal injection of AAV-IFN-β had a potent anti-tumor effect in vivo. These data suggest that AAV-mediated delivery of IFN-β may provide a complementary approach to systemic chemotherapy which is the standard of care for retinoblastoma around the world.

AB - Interferon-β (IFN-β) has been found to have anti-tumor properties against a variety of malignancies through different mechanisms. However, clinical trials involving systemic administration of IFN-β have been hampered by secondary toxicity and the short half-life of IFN-β in the circulation. In order to circumvent these limitations, we have developed an adeno-associated viral (AAV) vector gene-therapy approach to deliver IFN-β to tumors. In this study, we tested the efficacy of AAV-mediated local delivery of IFN-β for the treatment of retinoblastoma in preclinical models. Retinoblastoma is an ideal candidate for gene-therapy-based anti-cancer treatment because target cell transduction and, therefore, IFN-β delivery can be contained within the ocular environment, thereby minimizing systemic toxicity. We report here that retinoblastoma cell lines exhibit pleiotropic responses to IFN-β consistent with previous studies on a variety of tumor cell lines. Intravitreal injection of AAV-IFN-β resulted in efficient retinal infection and sustained IFN-β production in the eye with minimal systemic exposure. Vector spread outside of the eye was not detected. Using our orthotopic xenograft model of retinoblastoma, we found that intravitreal injection of AAV-IFN-β had a potent anti-tumor effect in vivo. These data suggest that AAV-mediated delivery of IFN-β may provide a complementary approach to systemic chemotherapy which is the standard of care for retinoblastoma around the world.

KW - AAV

KW - Gene therapy

KW - Interferon-β

KW - Retinoblastoma

UR - http://www.scopus.com/inward/record.url?scp=65249152968&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65249152968&partnerID=8YFLogxK

U2 - 10.1007/s12017-009-8059-0

DO - 10.1007/s12017-009-8059-0

M3 - Article

C2 - 19306089

AN - SCOPUS:65249152968

VL - 11

SP - 43

EP - 52

JO - NeuroMolecular Medicine

JF - NeuroMolecular Medicine

SN - 1535-1084

IS - 1

ER -